Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, April 16, 2024 · 704,217,770 Articles · 3+ Million Readers

Tabula Rasa HealthCare President and Co-Founder Named A Fellow of the College of Physicians of Philadelphia

Orsula V. Knowlton, PharmD, MBA Officially Inducted May 4, 2018

MOORESTOWN, N.J., May 25, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ:TRHC) President Orsula V. Knowlton, PharmD, MBA, was inducted into the College of Physicians of Philadelphia at College Night Gala held May 4, 2018.

Known as the “birthplace of American Medicine,” the College of Physicians, founded in 1787, is one of the oldest professional medical organizations in the country.  Its mission as a non-profit is “to promote the heritage and future of health and medicine.”

To become a Fellow, the inductee must be regarded as “a learned and dedicated physician, scientist, scholar, practitioner, or provider motivated by the interests of their patients, students and the public.”

Dr. Knowlton is the Co-founder, President, and Chief Marketing/New Business Development Officer for Tabula Rasa HealthCare (TRHC), a healthcare technology company optimizing medication safety by deploying new, medication risk mitigation software solutions and proprietary medication decision support tools.

Prior to TRHC, Dr. Knowlton was a key member of the start-up management team of excelleRx, a hospice medication management and pharmacy distribution company.  During her tenure as Vice President, Chief Marketing, Strategy and Business Development Officer, from 1995 – 2007, the Company grew to service over 85,000 hospice patients in 49 states. The Company was purchased by a Fortune 500 company in 2005.

Dr. Knowlton has published widely, including papers, book chapters and articles. She co-authored the first published consensus guidelines on the standards for anticoagulation management centers, in conjunction with the Anticoagulation Forum. Recently, she co-authored an article based on a study of 296 individuals, aged 55 and older, enrolled in community-based PACE centers nationwide, who underwent PGx testing as part of their medical care. The article was published online March 5, 2018 in Journal of the American Pharmacists Association, https://www.pharmacist.com/node/1444711, and in the Journal’s May/June print issue https://www.japha.org/current.

Active in the Philadelphia and South Jersey communities, Dr. Knowlton was named a “Women of Distinction” 2006 by the Philadelphia Business Journal, “NJ’s Best 50 Women in Business 2008,” winner of NJ Garden State “Entrepreneur Excellence Award 2013” SNJ Business People, “Exceptional Entrepreneur Award” 2014, “Citizen of the Year” by the Garden State Council Chapter of the Boy Scouts of America, 2016, and “Community Partners of the Year” by the Non-profit Development Center of Southern New Jersey, 2016 .  

Dr. Knowlton received her Bachelor of Science in Pharmacy and Doctorate in Pharmacy from the University of the Sciences College of Pharmacy and her Masters of Business Administration from Temple University’s Fox School of Business Executive Program.

About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.

Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Media Contact Investors
Dianne Semingson                                                                                                Bob East or Asher Dewhurst 
dsemingson@TRHC.com  Westwicke Partners
T: 215-870-0829  T: 443-213-0500


  

 

Primary Logo

Powered by EIN News
Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release